Negative impactCompany
Moderna stock crashes 25%, loses about $24 billion after cancer vaccine data leak
Economic Times 2 hrs ago·22 Oct 2026, 8:11 pm
Moderna's shares plunged more than a quarter after details of its joint melanoma vaccine trial with Merck became public. The data leak revealed early-stage results showing the vaccine, combined with Merck's Keytruda, cut the rate of cancer recurrence.
The sell‑off wiped out roughly $24 billion of market capitalisation, snapping a strong rally the company had enjoyed this year. Investors reacted quickly because the information moved from a private briefing to the open market, prompting a typical profit‑taking response.
Going forward, market participants will watch for formal regulatory filings, larger Phase III data releases and any updates on the commercial partnership between Moderna and Merck. The outcome could influence both biotech valuations and broader sentiment toward cancer‑immunotherapy stocks.
Excerpt from Economic Times
Moderna’s stock price dropped over 25% after trial results for its personalized melanoma vaccine with Merck were disclosed. The decline erased approximately $24 billion from Moderna’s market value, ending a significant rally this year. Analysts noted that this reaction was expected as investors often sell after news…Read the original at Economic Times
Key takeaways
- Category: Company.
- AI reads the tone as negative (potentially bearish) for the stock.
- Assessed as a significant, market-relevant update.
Why it matters
A meaningful update worth tracking. The tone is negative — watch for downside reaction. Use the price and stock snapshot to gauge how the market is responding.
